Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa
FDA recently guided Company to accelerate Phase 3 trial for EB-101 autologous cell therapy Breakthrough Therapy designation enables priority review and expedites approval process EB-101 has demonstrated significant efficacy in treated patients for over 2 …